Related Experiment Video
Updated: Nov 25, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status
Foteini V Karakontaki1, Efstratios S Panselinas2, Vlasios S Polychronopoulos1
1Department of Pulmonary Medicine, Hygeia Hospital, Athens, Greece.
Abstract:
Autoimmune rheumatic diseases (ARD) are characterized by systemic manifestations and multiple organ involvement, including the lung. Interstitial Lung Disease (ILD) is a cardinal manifestation of lung involvement in patients with ARD and is associated with significant morbidity and mortality. Corticosteroids and immunosuppressive drugs are used as first -line treatment. Targeted therapies, such as biological disease modifying antirheumatic drugs (DMARDS) and anti- fibrotic agents are new treatment options. In this review we discuss the role of targeted therapies in patients with ILD secondary to ARD.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Targeted Cancer Therapies
There are several types of targeted therapies against...

